reading TRIUMPH threads from 2024 and half of it aged badly
reading TRIUMPH threads from 2024 and half of it aged badly, which sounds obvious until you try to state the evidence for it.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Kept a log specifically because there is so little published. It is one person and it is not data.
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
heart rate is the thing people report watching
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
That is body weight change, not fat mass.
clara_weiss is right about the escalation being the variable. It explains most of the difficult reports here.
the phase 2 numbers were striking and they were also 48 weeks in a small population
dose escalation in the trials was slow for a reason
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.